-
公开(公告)号:TR200103457T2
公开(公告)日:2002-04-22
申请号:TR200103457
申请日:2000-05-24
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K31/496 , A61K31/505 , A61K31/506 , A61K31/5377 , A61P1/04 , A61P1/08 , A61P9/00 , A61P11/06 , A61P17/02 , A61P19/02 , A61P25/00 , A61P25/06 , A61P25/16 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/36 , A61P27/00 , A61P27/02 , A61P29/00 , A61P37/08 , A61P43/00 , C07D213/00 , C07D239/00 , C07D239/28 , C07D239/32 , C07D239/34 , C07D239/38 , C07D239/42 , C07D239/48 , C07D295/00 , C07D401/04 , C07D403/04
Abstract: The invention provides compounds of the formulawhereinR1 is hydrogen or halogen;R2 is hydrogen, halogen, lower alkyl or lower alkoxy;R1 and R2 may together be -CH=CH-CH=CH-, wherein R1 and R2 together with the two carbon ring atoms to which they are attached form a fused ring;R3 is halogen, trifluoromethyl, lower alkyl or lower alkoxy;R4/R4' are each independently hydrogen or lower alkyl;R5 is lower alkyl, lower alkoxy, amino, phenyl, hydroxy-lower alkyl, cyano-lower alkyl, carbamoyl-lower alkyl, pyridyl, pyrimidyl, -(CH2)n-piperazinyl, which is optionally substituted by one or two lower alkyl groups or by hydroxy-lower alkyl, -(CH2)n-morpholinyl, -(CH2)n-piperidinyl, -(CH2)n+1-imidazolyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, -NH-(CH2)n+1N(R4'')2, -(CH2)n+1N(R4'')2, -O-(CH2)n+1-morpholinyl, -O-(CH2)n+1-piperidinyl or -O-(CH2)n+1N(R4'')2, wherein R4'' is hydrogen or lower alkyl; andn is 0-2;X is -C(O)N(R4'')- or -N(R4'')C(O)-;and to pharmaceutically acceptable acid addition salts thereof.It has been shown that the compounds have a good affinity to the NK-1 receptor and may therefore used for the treatment of diseases related to this receptor.
-
42.
公开(公告)号:PE20020298A1
公开(公告)日:2002-04-17
申请号:PE2001000533
申请日:2001-06-07
Applicant: HOFFMANN LA ROCHE
Inventor: GALLEY GUIDO , KOLCZEWSKI SABINE , HOFFMANN TORSTEN , GODEL THIERRY , ROEVER STEPHAN , GOERGLER ANNICK
IPC: A61K31/437 , A61K31/445 , A61K31/4747 , A61P1/04 , A61P9/00 , A61P11/00 , A61P11/06 , A61P25/06 , A61P25/28 , A61P25/36 , A61P27/02 , A61P27/16 , A61P29/00 , A61P37/08 , A61P43/00 , C07D471/10
Abstract: SE REFIERE A DERIVADOS DE 1,3,8-TRIAZA-ESPIRO[4,5]DECAN-4-ONA DE FORMULA I DONDE R1 ES H, ALQUILO, ALQUENILO, FENILO, (CH2)m-HETEROCICLO, (CH2)m-HETEROARILO, (CH2)mCONRR', ENTRE OTROS; R2 ES H, ALQUILO, HALOGENO, ALCOXILO; R3 ES ALQUILO, ALCOXILO, HALOGENO, CF3; R Y R' SON H, ALQUILO; X ES N, C=, CH; X1 Y X2 SON H, OH, ALCOXILO O JUNTOS SON OXO; Y1 Y Y2 SON H, ALQUILO, (CH2)m-FENILO O JUNTOS SON OXO; Z ES ENLACE, CH2, CO; m ES 0-4; n ES 2-3; n' ES 0-2. SON COMPUESTOS PREFERIDOS 8-(3,5-BIS-TRIFLUOROMETIL-BENZOIL)-3-(4,6-DIMETOXI-1,3,5)TRIACIN-2-IL)-1-IL)-1-FENIL-1,3,8-TRIAZA-ESPIRO[4,5]DECAN-4-ONA; 8-(3,5-BIS-TRIFLUOROMETIL-BENZOIL)-1-(2-CLORO-FENIL)-3-(4,6-DIMETOXI-[1,3,5]TRIACIN-2-IL)-1,3,8-TRIAZA-ESPIRO[4,5]DECAN-4-ONA, ENTRE OTROS; TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS I SON ANTAGONISTAS DE RECEPTORES NK-1 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL COMO DEPRESION, EMESIS
-
43.
公开(公告)号:PE02982002A1
公开(公告)日:2002-04-17
申请号:PE0005332001
申请日:2001-06-07
Applicant: HOFFMANN LA ROCHE
Inventor: GALLEY GUIDO , KOLCZEWSKI SABINE , HOFFMANN TORSTEN , GODEL THIERRY , ROEVER STEPHAN , GOERGLER ANNICK
IPC: A61K31/437 , A61K31/445 , A61K31/4747 , A61P1/04 , A61P9/00 , A61P11/00 , A61P11/06 , A61P25/06 , A61P25/28 , A61P25/36 , A61P27/02 , A61P27/16 , A61P29/00 , A61P37/08 , A61P43/00 , C07D471/10
CPC classification number: C07D471/10 , A61K9/0031 , A61K9/02 , A61K9/2018 , A61K9/4858
Abstract: SE REFIERE A DERIVADOS DE 1,3,8-TRIAZA-ESPIRO[4,5]DECAN-4-ONA DE FORMULA I DONDE R1 ES H, ALQUILO, ALQUENILO, FENILO, (CH2)m-HETEROCICLO, (CH2)m-HETEROARILO, (CH2)mCONRR', ENTRE OTROS; R2 ES H, ALQUILO, HALOGENO, ALCOXILO; R3 ES ALQUILO, ALCOXILO, HALOGENO, CF3; R Y R' SON H, ALQUILO; X ES N, C=, CH; X1 Y X2 SON H, OH, ALCOXILO O JUNTOS SON OXO; Y1 Y Y2 SON H, ALQUILO, (CH2)m-FENILO O JUNTOS SON OXO; Z ES ENLACE, CH2, CO; m ES 0-4; n ES 2-3; n' ES 0-2. SON COMPUESTOS PREFERIDOS 8-(3,5-BIS-TRIFLUOROMETIL-BENZOIL)-3-(4,6-DIMETOXI-1,3,5)TRIACIN-2-IL)-1-IL)-1-FENIL-1,3,8-TRIAZA-ESPIRO[4,5]DECAN-4-ONA; 8-(3,5-BIS-TRIFLUOROMETIL-BENZOIL)-1-(2-CLORO-FENIL)-3-(4,6-DIMETOXI-[1,3,5]TRIACIN-2-IL)-1,3,8-TRIAZA-ESPIRO[4,5]DECAN-4-ONA, ENTRE OTROS; TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS I SON ANTAGONISTAS DE RECEPTORES NK-1 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL COMO DEPRESION, EMESIS
-
公开(公告)号:CZ20013190A3
公开(公告)日:2002-02-13
申请号:CZ20013190
申请日:2000-02-28
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: C07D295/14 , A61K31/166 , A61K31/167 , A61K31/495 , A61K31/496 , A61P1/04 , A61P1/08 , A61P11/06 , A61P25/24 , A61P25/28 , A61P29/00 , A61P37/08 , A61P43/00 , C07C41/01 , C07C43/174 , C07C209/06 , C07C209/50 , C07C211/29 , C07C211/45 , C07C217/54 , C07C231/02 , C07C231/08 , C07C233/11 , C07C233/15 , C07C233/44 , C07C233/66 , C07C235/42 , C07D295/155 , A61P25/06 , A61P25/36 , A61P11/00
Abstract: The invention relates to compounds of the formulawhereinR is hydrogen, lower alkyl, lower alkoxy halogen, amino, -N(R6)2 or trifluoromethyl;R1 is hydrogen lower alkoxy or halogen,R and R1 may be together -CH=CH-CH=CH-;R2 is halogen, lower alkyl or trifluoromethyl;R3 is hydrogen or lower alkyl;R4 is hydrogen or a cyclic tertiary amine, optionally substituted by lower alkyl;R5 is hydrogen, nitro, amino or -N(R6)2;R6 is hydrogen or lower alkyl,X is -C(O)N(R6)-, -(CH2)nO-, (CH2)nN(R6)-, -N(R6)C(O)- or -N(R6)(CH2)n-; andn is 1 or 2;and pharmaceutically acceptable acid addition salts thereof.The compounds of formula I may be used for the treatment of diseases related to the NK-1 receptor.
-
公开(公告)号:SV2002000024A
公开(公告)日:2002-01-23
申请号:SV2000000024
申请日:2000-02-23
Applicant: HOFFMANN LA ROCHE
Inventor: BOS MICHAEL , BRANCA QUIRICO , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K20060101 , A61K31/44 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/444 , A61K31/445 , A61K31/455 , A61K31/496 , A61P1/00 , A61P9/00 , A61P11/00 , A61P25/00 , A61P25/04 , A61P25/28 , A61P25/30 , A61P27/02 , A61P29/00 , A61P43/00 , C07D20060101 , C07D211/38 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/63 , C07D213/65 , C07D213/74 , C07D213/75 , C07D213/78 , C07D213/82 , C07D401/04 , C07D401/12 , C07D413/12 , C07D413/14
Abstract: LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA GENERAL, VER FORMULA, EN DONDER ES HIDROGENO, ALQUILO INFERIOR, ALCOXI INFERIOR, HALOGENO O TRIFLUOROMETILO;R1 ES HIDROGENO O HALOGENO; OR Y R1 PUEDEN SER CONJUNTAMENTE -CH=CH-CH=CH-;R2 Y R2' PUEDEN SER CONJUNTAMENTE -CH=CH-CH=CH-, SUSTITUIDO OPCIONALMENTE POR UNO O DOS SUSTITUYENTES SELECCIONADOS DEL ALQUILO INFERIOR O DEL ALCOXI INFERIOR;R3 ES HIDROGENO, ALQUILO INFERIOR O FORMA UN GRUPO CICLOALQUILO;R4 ES HIDROGENO, -N(R5)2,-N(R5)(CH2)nOH,-N(R5)S(O)2 ALQUILO INFERIOR, -N(R5)S(O)2-FENILO,-N=CH-N(R5)2, N(R5)C(O)R5 O UNA AMINA TERCIARIA CICLICA DEL GRUPO, VER FORMULA, R5 ES INDEPENDIENTEMENTE, HIDROGENO, C3-6-CICLOALQUILO, BENCILO O ALQUILO INFERIOR;R6 ES HIDROGENO, HIDROXI, ALQUILO INFERIOR, -(-CH2)nCOO-ALQUILO INFERIOR, -N(R5)CO-ALQUILO INFERIOR, HIDROXI-ALQUILO INFERIOR, CIANO,-(CH2)nO(CH2)nOH-CHO O UN GRUPO HETEROCICLICO DE 5 O 6 MIEMBROS, UNIDO OPCIONALMENTE POR UN GRUPO ALQUILENO,X ES -C(O)N(R5-,-(CH2)mO-,-(CH2)mN(R5)-,-N(R5)C(O), O -N(R5)(CH2)m-;N ES 0-4; YM ES 1 O 2;Y SALES DERIVADAS DE UNA ADICION ACIDA FARMACEUTICAMENTE ACEPTABLES. LOS COMPUESTOS DE LA FORMULA I MUESTRAN UNA MAYOR AFINIDAD POR EL RECEPTOR DE NK-1. ESTOS SE PUEDEN USAR PARA EL TRATAMIENTO DE ENFERMEDADES QUE ESTEN RELACIONADAS CON ANTAGONISTAS DEL RECEPTOR DE NK-1.
-
公开(公告)号:NO20015700L
公开(公告)日:2001-11-22
申请号:NO20015700
申请日:2001-11-22
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K31/496 , A61K31/505 , A61K31/506 , A61K31/5377 , A61P1/04 , A61P1/08 , A61P9/00 , A61P11/06 , A61P17/02 , A61P19/02 , A61P25/00 , A61P25/06 , A61P25/16 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/36 , A61P27/00 , A61P27/02 , A61P29/00 , A61P37/08 , A61P43/00 , C07D213/00 , C07D239/00 , C07D239/28 , C07D239/32 , C07D239/34 , C07D239/38 , C07D239/42 , C07D239/48 , C07D295/00 , C07D401/04 , C07D403/04
Abstract: The invention provides compounds of the formulawhereinR1 is hydrogen or halogen;R2 is hydrogen, halogen, lower alkyl or lower alkoxy;R1 and R2 may together be -CH=CH-CH=CH-, wherein R1 and R2 together with the two carbon ring atoms to which they are attached form a fused ring;R3 is halogen, trifluoromethyl, lower alkyl or lower alkoxy;R4/R4' are each independently hydrogen or lower alkyl;R5 is lower alkyl, lower alkoxy, amino, phenyl, hydroxy-lower alkyl, cyano-lower alkyl, carbamoyl-lower alkyl, pyridyl, pyrimidyl, -(CH2)n-piperazinyl, which is optionally substituted by one or two lower alkyl groups or by hydroxy-lower alkyl, -(CH2)n-morpholinyl, -(CH2)n-piperidinyl, -(CH2)n+1-imidazolyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, -NH-(CH2)n+1N(R4'')2, -(CH2)n+1N(R4'')2, -O-(CH2)n+1-morpholinyl, -O-(CH2)n+1-piperidinyl or -O-(CH2)n+1N(R4'')2, wherein R4'' is hydrogen or lower alkyl; andn is 0-2;X is -C(O)N(R4'')- or -N(R4'')C(O)-;and to pharmaceutically acceptable acid addition salts thereof.It has been shown that the compounds have a good affinity to the NK-1 receptor and may therefore used for the treatment of diseases related to this receptor.
-
公开(公告)号:NO20014356A
公开(公告)日:2001-09-07
申请号:NO20014356
申请日:2001-09-07
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: C07D295/14 , A61K31/166 , A61K31/167 , A61K31/495 , A61K31/496 , A61P1/04 , A61P1/08 , A61P11/06 , A61P25/24 , A61P25/28 , A61P29/00 , A61P37/08 , A61P43/00 , C07C41/01 , C07C43/174 , C07C209/06 , C07C209/50 , C07C211/29 , C07C211/45 , C07C217/54 , C07C231/02 , C07C231/08 , C07C233/11 , C07C233/15 , C07C233/44 , C07C233/66 , C07C235/42 , C07D295/155
CPC classification number: C07D295/155 , C07C217/54 , C07C233/15 , C07C233/44 , C07C233/66 , C07C235/42
-
公开(公告)号:NO20014096L
公开(公告)日:2001-08-23
申请号:NO20014096
申请日:2001-08-23
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K31/167 , C07C211/44 , A61K31/44 , A61P25/00 , A61P29/00 , C07C211/54 , C07C233/29 , C07C233/33 , C07C233/44 , C07C317/14 , C07C317/40 , C07C323/41 , C07D213/75 , C07D213/79 , C07D213/81 , C07D295/12 , C07D295/135 , C07D401/04 , C07D213/00
Abstract: The present invention is a series of compounds formed from phenyl substituted pyridine or benzene derivatives and their pharmaceutically acceptable salts. These compounds have shown high affinity as antagonists to the NK-1 receptor.
-
公开(公告)号:AT203536T
公开(公告)日:2001-08-15
申请号:AT95103028
申请日:1995-03-03
Applicant: HOFFMANN LA ROCHE
Inventor: GODEL THIERRY , HUNKELER WALTER , STADLER HEINZ , WIDMER ULRICH
IPC: A61K31/41 , A61K31/55 , A61K31/5517 , A61P21/02 , A61P25/08 , A61P25/20 , A61P43/00 , C07D487/02 , C07D487/04 , C07D495/12 , C07D495/14 , C07D498/14 , C07D243/00 , C07D235/00 , C07D333/00
Abstract: Aminomethyl-substd. oxadiazolyl-imidazodiazepines of formula (I) and their addn salts are new: A and C atoms alpha and beta form a gp of formula e.g. (A ):Q = a gp. of formula e.g. (Q ):R , R = H; lower alkyl,etc.;or NR R = 5-8 membered heterocycle opt. contg. a further hetero atom or carrying a fused benzene ring; R = H and R = lower alkyl; or R +R = H; halo;etc.; and C atom gamma has the S configuration when R is other than H.
-
公开(公告)号:GR3035703T3
公开(公告)日:2001-07-31
申请号:GR20010400551
申请日:2001-04-05
Applicant: HOFFMANN LA ROCHE
Inventor: GODEL THIERRY , HARTMAN DEBORAH , RIEMER CLAUS
IPC: A61K31/44 , C07D211/70 , A61K31/4418
Abstract: A method of treating or preventing illnesses caused by a disorder of the dopamine system. The method comprises administering to a host requiring such treatment or prevention an effective amount of a pharmaceutical composition comprising a compound of the formula I wherein R1 is hydrogen, lower-alkyl, halogen, lower-alkoxy or nitro; R2 is hydrogen, lower alkyl or trifluoromethyl; and R3 is hydrogen, lower alkyl, trifluoromethyl, benzyl, hydroxy-lower-alkyl, lower alkoxy, lower-alkyl-carbonyl-amino, carbonyl-lower-alkyl, benzyl, di-lower-alkyl-amino-carbonyl, carbonylamino or amino-carbonyl-amino; or R2 and R3 together optionally are a fused benzene ring and R4 is hydrogen or halogen, or a pharmaceutically acceptable salt of a compound of formula I, and a pharmaceutically inert carrier material.
-
-
-
-
-
-
-
-
-